To correct hypofibrinogenemia due to DIC, which product is required?

To correct hypofibrinogenemia resulting from disseminated intravascular coagulation (DIC), cryoprecipitated AHF (antihemophilic factor) is the most appropriate choice. Cryoprecipitate is a blood product rich in fibrinogen, factor VIII, and von Willebrand factor, making it especially effective for raising fibrinogen levels in patients with hypofibrinogenemia.

DIC often leads to decreased fibrinogen levels because of its consumption during the abnormal clotting process, resulting in a higher risk for bleeding. Administering cryoprecipitate directly addresses the low fibrinogen levels by providing the necessary factors that support clot formation and stabilization.

While fresh frozen plasma can help restore other clotting factors and provides some fibrinogen, it contains lower concentrations compared to cryoprecipitate. Whole blood contains all components of blood but is rarely used when specific factor replacement is needed and its use is more aligned with volume resuscitation than treating specific deficiencies. Platelets are essential for clot formation but do not directly replenish fibrinogen levels, making them less relevant in this context. Hence, cryoprecipitate is the optimal choice for correcting hypofibrinogenemia due